Expert Review of Cardiovascular Therapy is a leading academic journal published by TAYLOR & FRANCIS INC, focusing on innovative and impactful research in the field of cardiovascular medicine. With an ISSN of 1477-9072 and an E-ISSN of 1744-8344, this journal serves as an essential resource for researchers, clinicians, and educators, offering a platform for the dissemination of critical advancements in cardiovascular therapy and internal medicine. Since its inception in 2003, the journal has maintained a reputable standing with a Q2 ranking in various categories including Cardiology and Cardiovascular Medicine, reflecting its influence and rigor in the field. The journal, which is based in the United Kingdom, does not currently offer Open Access options, ensuring that its content is accessible primarily to subscribers. With its commitment to high-quality, peer-reviewed articles, Expert Review of Cardiovascular Therapy is dedicated to bridging the gap between experimental research and clinical application, thereby enhancing patient care and therapeutic outcomes in cardiovascular health.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.

The Journal fur Kardiologie, published by KRAUSE & PACHERNEGG GMBH, is a pivotal resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 1024-0098 and an E-ISSN of 1680-936X, this journal has played a significant role in disseminating valuable research and clinical studies from 1998 until its coverage discontinuation in Scopus in 2017. Despite its Scopus rank being relatively low at #316/324 in its category, it continues to serve as a platform for emerging cardiology research. The journal’s scope encompasses various aspects of cardiovascular health, providing insights that are crucial for researchers, professionals, and students alike seeking to advance their knowledge and practice in cardiology. While the journal is not open access, its contributions to the field are essential for those looking to stay informed about the latest developments in cardiovascular medicine.

The Monaldi Archives for Chest Disease, published by PAGEPRESS PUBL, is a vital resource for researchers and healthcare professionals dedicated to the fields of cardiology and pulmonary medicine. With an ISSN of 1122-0643 and an E-ISSN of 2532-5264, this Open Access journal has been committed to disseminating high-quality research since 2004, ensuring that findings in chest disease are easily accessible to a global audience. Based in Italy, the journal features contributions that reflect a broad scope of topics within its fields, achieving a Q3 ranking in both Cardiology and Cardiovascular Medicine, as well as in Pulmonary and Respiratory Medicine as of 2023. The journal's Scopus ranks place it at 168th out of 387 in its cardiology category and 83rd out of 155 in pulmonary medicine, indicating its relevance in the academic landscape. With its commitment to advancing knowledge and practice, the Monaldi Archives for Chest Disease stands as an essential platform for publication and dialogue in chest disease research, appealing to a diverse audience of scholars and practitioners.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

CIRCULATION RESEARCH is a premier journal dedicated to advancing the field of cardiovascular science, focusing on innovative research in cardiology and physiology. Published by Lippincott Williams & Wilkins, this esteemed journal has been a cornerstone of cardiovascular research since its inception in 1953, maintaining rigorous standards of scholarly excellence. With an impressive impact factor and ranking in the top quartiles for both Cardiology and Cardiovascular Medicine (Q1) and Physiology (Q1), it holds a significant position in the Scopus database. This journal features cutting-edge studies aimed at understanding the mechanisms of cardiovascular health and disease, promoting the translation of research into clinical practice. Weekly issues provide practitioners and researchers alike with vital insights to keep abreast of the latest developments. Although it does not offer open access, CIRCULATION RESEARCH remains vital for professionals striving to enhance their knowledge and impact in the ever-evolving landscape of cardiovascular medicine.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.